VistaGen Therapeutics, Inc.
VTGN
Price:
$4.28
Market Cap:
$140.27M
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also compris...[Read more]
Industry
Biotechnology
IPO Date
2011-06-21
Stock Exchange
NASDAQ
Ticker
VTGN
PE Ratio
[-2.23]
ROE
[-90.65%]
Current Ratio
[5.79]
Dividend Yield
[0%]
Enterprise Value
[78.69M]
Dividend History
The ROE as of December 2025 (TTM) for VistaGen Therapeutics, Inc. (VTGN) is -90.65%
According to VistaGen Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -90.65%. This represents a change of 291.58% compared to the average of -23.15% of the last 4 quarters.
VistaGen Therapeutics, Inc. (VTGN) Historical ROE (quarterly & annually)
How has VTGN ROE performed in the past?
The mean historical ROE of VistaGen Therapeutics, Inc. over the last ten years is -95.42%. The current -90.65% ROE has changed -5.00% with respect to the historical average. Over the past ten years (40 quarters), VTGN's ROE was at its highest in in the June 2017 quarter at 373.32%. The ROE was at its lowest in in the December 2018 quarter at -426.32%.
Average
-95.42%
Median
-73.43%
Minimum
-1665.39%
Maximum
1.59%
VistaGen Therapeutics, Inc. (VTGN) ROE by Quarter and Year
Discovering the peaks and valleys of VistaGen Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.25%
Maximum Annual ROE = 1.59%
Minimum Annual Increase = -205.00%
Minimum Annual ROE = -1665.39%
| Year | ROE | Change |
|---|---|---|
| 2025 | -73.05% | 184.32% |
| 2024 | -25.69% | -94.76% |
| 2023 | -490.46% | 564.55% |
| 2022 | -73.80% | 278.52% |
| 2021 | -19.50% | -105.38% |
| 2020 | 362.59% | -204.33% |
| 2019 | -347.55% | 67.56% |
| 2018 | -207.41% | -87.55% |
| 2017 | -1665.39% | -205.00% |
| 2016 | 1.59% | 2.25% |
VistaGen Therapeutics, Inc. (VTGN) Average ROE
How has VTGN ROE performed in the past?
The current ROE of VistaGen Therapeutics, Inc. (VTGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-196.40%
5-year avg
-136.50%
10-year avg
-95.42%
VistaGen Therapeutics, Inc. (VTGN) ROE vs. Peers
How is VTGN’s ROE compared to its peers?
VistaGen Therapeutics, Inc.’s ROE is greater than Spero Therapeutics, Inc. (-125.91%), greater than Seer, Inc. (-26.48%), less than Seres Therapeutics, Inc. (15.31%), greater than Opus Genetics, Inc. (-366.68%), greater than Cognition Therapeutics, Inc. (-251.23%), greater than TuHURA Biosciences, Inc. (-393.18%), less than Agenus Inc. (59.64%), greater than Actuate Therapeutics Inc (-2924.50%), greater than Acumen Pharmaceuticals, Inc. (-97.41%), greater than Inovio Pharmaceuticals, Inc. (-80970.00%),
| Company | ROE | Market cap |
|---|---|---|
| -125.91% | $128.44M | |
| -26.48% | $107.12M | |
| 15.31% | $157.07M | |
| -366.68% | $153.73M | |
| -251.23% | $129.50M | |
| -393.18% | $100.77M | |
| 59.64% | $137.64M | |
| -2924.50% | $170.84M | |
| -97.41% | $119.94M | |
| -80970.00% | $108.25M |
Build a custom stock screener for VistaGen Therapeutics, Inc. (VTGN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VistaGen Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
VistaGen Therapeutics, Inc. (VTGN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like VistaGen Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is VistaGen Therapeutics, Inc.'s ROE?
How is the ROE calculated for VistaGen Therapeutics, Inc. (VTGN)?
What is the highest ROE for VistaGen Therapeutics, Inc. (VTGN)?
What is the 3-year average ROE for VistaGen Therapeutics, Inc. (VTGN)?
What is the 5-year average ROE for VistaGen Therapeutics, Inc. (VTGN)?
How does the current ROE for VistaGen Therapeutics, Inc. (VTGN) compare to its historical average?